Roche and GE Healthcare have launched the new NAVIFY Tumor Board 2.0 with medical imaging capabilities to facilitate personalised treatment for cancer patients.
Tumour boards are multi-disciplinary teams that determine treatment plans for people with cancer. The new solution has been designed to provide a comprehensive view of individual patients on a single platform.
The partners integrated GE Healthcare’s medical image viewer into the new solution to give radiologists the ability to upload patient records to the same dashboard as where files from other cancer care disciplines are stored.
Such compilation of patient diagnostic information in one location is expected to enable faster reviews by tumour boards in limited time.
Roche Diagnostics CEO Michael Heuer said: “This new version of NAVIFY Tumor Board is the first product developed in partnership with GE Healthcare and demonstrates our shared vision of accelerating personalised healthcare.
“Our mutual focus is on delivering clinical decision support solutions that enable healthcare professionals to make faster, more confident decisions, allowing more personalised treatment based on truly integrated diagnostics.”
As part of the alliance, Roche combined its advanced lab testing expertise with GE Healthcare’s medical imaging and monitoring capabilities.
The partners intend to develop products for enhanced integration and analysis of comprehensive lab and medical imaging data, patient records, real-time monitoring and the latest research outcomes.
NAVIFY Tumor Board 2.0 has been initially introduced in the US and Canada, with plans to expand to other markets in the near future.
GE Healthcare Imaging president and CEO Tom McGuinness said: “Workflows around tumour boards can be inefficient, and we hope this single, holistic dashboard, including patient data and images, will enable oncology teams to align more quickly on the most optimal diagnosis and treatment plan for the benefit of each patient.”
Roche launched the initial NAVIFY Tumor Board in October 2017 in the US, UK, Germany, Spain, Sweden and Switzerland. The solution was intended to provide a clinical workflow and decision support software.